Shopping Cart 0
Cart Subtotal
USD 0

Pertussis (Whooping Cough)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pertussis (Whooping Cough)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough)-Pipeline Review, H2 2017, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 5, 7, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pertussis (Whooping Cough)-Overview

Pertussis (Whooping Cough)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pertussis (Whooping Cough)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pertussis (Whooping Cough)-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech International Ltd

Biological E Ltd

Cadila Healthcare Ltd

DBV Technologies SA

GlaxoSmithKline Plc

Green Cross Corp

Indian Immunologicals Ltd

Kaketsuken

LG Chem Ltd

NanoBio Corp

Sanofi

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Synthetic Biologics Inc

Wockhardt Ltd

Pertussis (Whooping Cough)-Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular)) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(hepatitis B + pertussis) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bladder cancer + pertussis + tuberculosis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTaP-IPV-HB-PRPT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GamLPV-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3111A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis (acellular) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis (acellular) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis (whole cell) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pertussis (Whooping Cough)-Dormant Projects

Pertussis (Whooping Cough)-Discontinued Products

Pertussis (Whooping Cough)-Product Development Milestones

Featured News & Press Releases

Aug 29, 2017: The HUG Completes the PertADO Trial Evaluating Pertagen, a New Recombinant Pertussis Vaccine, in Adolescents in Switzerland

Jul 05, 2017: ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study

Mar 30, 2017: DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination

Dec 13, 2016: Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)

Nov 30, 2016: GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

Nov 17, 2016: DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis

Sep 06, 2016: DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination

Jul 27, 2016: Nanobio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting

Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough

Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine

Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5

Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015

Nov 24, 2014: CanSinotech submitted CTA of ?Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed? to CFDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Pertussis (Whooping Cough), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pertussis (Whooping Cough), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pertussis (Whooping Cough)-Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by Bharat Biotech International Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by Biological E Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by Cadila Healthcare Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by DBV Technologies SA, H2 2017

Pertussis (Whooping Cough)-Pipeline by GlaxoSmithKline Plc, H2 2017

Pertussis (Whooping Cough)-Pipeline by Green Cross Corp, H2 2017

Pertussis (Whooping Cough)-Pipeline by Indian Immunologicals Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by Kaketsuken, H2 2017

Pertussis (Whooping Cough)-Pipeline by LG Chem Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by NanoBio Corp, H2 2017

Pertussis (Whooping Cough)-Pipeline by Sanofi, H2 2017

Pertussis (Whooping Cough)-Pipeline by Sanofi Pasteur SA, H2 2017

Pertussis (Whooping Cough)-Pipeline by Serum Institute of India Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017

Pertussis (Whooping Cough)-Pipeline by Synthetic Biologics Inc, H2 2017

Pertussis (Whooping Cough)-Pipeline by Wockhardt Ltd, H2 2017

Pertussis (Whooping Cough)-Dormant Projects, H2 2017

Pertussis (Whooping Cough)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Pertussis (Whooping Cough)-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech International Ltd

Biological E Ltd

Cadila Healthcare Ltd

DBV Technologies SA

GlaxoSmithKline Plc

Green Cross Corp

Indian Immunologicals Ltd

Kaketsuken

LG Chem Ltd

NanoBio Corp

Sanofi

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Synthetic Biologics Inc

Wockhardt Ltd